NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NTC

More Like This

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery

PR Newswire associated0

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

PR Newswire associated0

NTC gives long term consistency to its ophtha portfolio with another MDR CE Certificate approval

PR Newswire associated0

NTC Ophthalmics lberica: Young ophthalmologists square in Zahara Los Atunes

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection